Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.Copyright ©ERS 2020.
About The Author
Matteo Bonini,Marcello Di Paolo,Diego Bagnasco,Ilaria Baiardini,Fulvio Braido,Marco Caminati,Elisiana Carpagnano,Marco Contoli,Angelo Corsico,Stefano Del Giacco,Enrico Heffler,Carlo Lombardi,Ilaria Menichini,Manlio Milanese,Nicola Scichilone,Gianenrico Senna,Giorgio W Canonica
Marcello Di Paolo
Stefano Del Giacco
Giorgio W Canonica